Vertex Pharmaceuticals (VRTX) Return on Capital Employed (2010 - 2026)
Vertex Pharmaceuticals' quarterly Return on Capital Employed came in at 21.1% in Q1 2026, up 2503.0% year-on-year from 0.81% in Q1 2025, and up 8.17% quarter-over-quarter from 19.51% in Q4 2025.
Vertex Pharmaceuticals has reported Return on Capital Employed for 17 years, with the latest figure at 21.1% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 2503.0% year-over-year to 21.1%; the trailing twelve-month figure through Mar 2026 stood at 21.1% (up 2503.0% YoY), and the FY2025 full-year result was 20.63%, up 2185.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 21.1%, up from 19.51% in the prior quarter.
- The five-year high for Return on Capital Employed was 33.0% in Q2 2022, with the low at 3.92% in Q1 2025.
- Average Return on Capital Employed over 5 years is 17.94%, with a median of 21.1% recorded in 2026.
- Year-over-year, Return on Capital Employed sank 2620 bps in 2024 and soared 2503 bps in 2026.
- Tracing VRTX's Return on Capital Employed over 5 years: stood at 29.33% in 2022, then tumbled by 30 bps to 20.51% in 2023, then slumped by 106 bps to 1.24% in 2024, then surged by 1677 bps to 19.51% in 2025, then gained by 8 bps to 21.1% in 2026.
- The last three Return on Capital Employed figures came in at 21.1% (Q1 2026), 19.51% (Q4 2025), and 19.99% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -21.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.10% |
| Dec 31, 2025 | 19.51% |
| Sep 30, 2025 | 19.99% |
| Jun 30, 2025 | 20.31% |
| Mar 31, 2025 | -3.92% |
| Dec 31, 2024 | -1.24% |
| Sep 30, 2024 | -1.57% |
| Jun 30, 2024 | -1.89% |
| Mar 31, 2024 | 21.47% |
| Dec 31, 2023 | 20.51% |
| Sep 30, 2023 | 22.23% |
| Jun 30, 2023 | 24.31% |
| Mar 31, 2023 | 26.04% |
| Dec 31, 2022 | 29.33% |
| Sep 30, 2022 | 30.67% |
| Jun 30, 2022 | 33.00% |
| Mar 31, 2022 | 25.16% |
| Dec 31, 2021 | 25.56% |
| Sep 30, 2021 | 25.23% |
| Jun 30, 2021 | 21.95% |
| Mar 31, 2021 | 30.27% |
| Dec 31, 2020 | 29.60% |
| Sep 30, 2020 | 30.41% |
| Jun 30, 2020 | 26.93% |
| Mar 31, 2020 | 23.22% |
| Dec 31, 2019 | 18.20% |
| Sep 30, 2019 | 13.15% |
| Jun 30, 2019 | 15.92% |
| Mar 31, 2019 | 14.81% |
| Dec 31, 2018 | 14.73% |
| Sep 30, 2018 | 18.17% |
| Jun 30, 2018 | 3.15% |
| Mar 31, 2018 | -0.64% |
| Dec 31, 2017 | 4.80% |
| Sep 30, 2017 | 1.47% |
| Jun 30, 2017 | 13.83% |
| Mar 31, 2017 | 12.13% |
| Dec 31, 2016 | 0.51% |
| Sep 30, 2016 | -4.49% |
| Jun 30, 2016 | -7.11% |
| Mar 31, 2016 | -15.93% |
| Dec 31, 2015 | -23.82% |
| Sep 30, 2015 | -27.93% |
| Jun 30, 2015 | -33.70% |
| Mar 31, 2015 | -33.29% |
| Dec 31, 2014 | -34.58% |
| Sep 30, 2014 | -29.05% |
| Jun 30, 2014 | -29.56% |
| Mar 31, 2014 | -21.06% |
| Dec 31, 2013 | -29.71% |
| Sep 30, 2013 | -31.15% |
| Jun 30, 2013 | -26.33% |
| Mar 31, 2013 | -23.91% |
| Dec 31, 2012 | 0.10% |
| Sep 30, 2012 | 13.47% |
| Jun 30, 2012 | 24.84% |
| Mar 31, 2012 | 19.36% |
| Dec 31, 2011 | 6.44% |
| Mar 31, 2011 | -57.22% |
| Dec 31, 2010 | -52.24% |
| Sep 30, 2010 | -46.31% |
| Jun 30, 2010 | -44.00% |
| Mar 31, 2010 | -37.08% |